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Abstract
Background
The global burden of pediatric severe respiratory illness is substantial, and influenza viruses
contribute to this burden. Systematic surveillance and testing for influenza among hospital-
ized children has expanded globally over the past decade. However, only a fraction of the
data has been used to estimate influenza burden. In this analysis, we use surveillance data
to provide an estimate of influenza-associated hospitalizations among children worldwide.
Methods and Findings
We aggregated data from a systematic review (n = 108) and surveillance platforms (n = 37)
to calculate a pooled estimate of the proportion of samples collected from children hospital-
ized with respiratory illnesses and positive for influenza by age group (<6 mo, <1 y, <2 y, <5
y, 5–17 y, and <18 y). We applied this proportion to global estimates of acute lower respira-
tory infection hospitalizations among children aged <1 y and <5 y, to obtain the number and
per capita rate of influenza-associated hospitalizations by geographic region and socio-eco-
nomic status.
Influenza was associated with 10% (95% CI 8%–11%) of respiratory hospitalizations in
children <18 y worldwide, ranging from 5% (95% CI 3%–7%) among children <6 mo to 16%
(95% CI 14%–20%) among children 5–17 y. On average, we estimated that influenza
results in approximately 374,000 (95% CI 264,000 to 539,000) hospitalizations in children
<1 y—of which 228,000 (95% CI 150,000 to 344,000) occur in children <6 mo—and
870,000 (95% CI 610,000 to 1,237,000) hospitalizations in children <5 y annually. Influ-
enza-associated hospitalization rates were more than three times higher in developing
countries than in industrialized countries (150/100,000 children/year versus 48/100,000).
However, differences in hospitalization practices between settings are an important limita-
tion in interpreting these findings.
Conclusions
Influenza is an important contributor to respiratory hospitalizations among young children
worldwide. Increasing influenza vaccination coverage among young children and pregnant
women could reduce this burden and protect infants <6 mo.
Introduction
Influenza virus infections are a substantial contributor to respiratory morbidity and mortality,
with the highest burden of severe disease experienced by those aged<5 y and65 y [1–3].
Until recently, however, estimates of influenza burden have been largely obtained from
resource-rich settings with temperate climates with clearly defined influenza seasonality, with
few estimates available from lower-income countries [4–6]. This lack of information on influ-
enza burden in resource-limited settings has hampered informed consideration of implementa-
tion of preventive measures such as vaccination.
In the last 10 y, however, the global expansion of influenza surveillance and laboratory
capacity for influenza testing by reverse transcription PCR has led to dramatic increases in
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testing in settings with previously sparse data. Many countries worldwide now perform hospi-
tal-based influenza surveillance among patients hospitalized with severe acute respiratory ill-
ness (SARI) [7–9]. These systems have proven useful in tracking influenza activity among
hospitalized patients, but only a fraction of the collected data has been used to estimate the bur-
den of influenza-associated hospitalizations. A 2011 meta-analysis using data from 16 popula-
tion-based research sites and published literature estimated that there were 1 million cases of
influenza-associated SARI episodes globally in children aged<5 y old in 2008. In this study,
the per capita rate of severe influenza illness in developing countries was at least double that of
industrialized countries [6]. This rate-based approach was mainly derived from sites with a
limited population at risk under surveillance, and therefore represented only a small fraction of
hospitals conducting surveillance for severe influenza disease globally.
We aimed to update the previous influenza burden estimates in young children, making full
use of updated and expanded surveillance data from the past decade (2003–2012), both before
and after the 2009 pandemic influenza emergence. We further aimed to extend previous studies
by providing global estimates of the prevalence of influenza among acute lower respiratory
infection (ALRI) hospitalizations among both younger (<5 y) and older (5–17 y) children.
Methods
We aggregated data from all eligible published etiologic studies of influenza-associated respira-
tory illness among hospitalized children, which we supplemented with data from a working
group of inpatient surveillance systems worldwide. We then calculated a final pooled estimate
of the proportion of tested samples that were positive for influenza by reverse transcription
PCR among children aged<18 y (referred to as proportion or percent positive), using age-
group-specific random-effects log-binomial regression models. Finally, we applied the aggre-
gate pooled proportion positive among children<1 and<5 y to age-specific denominators of
global hospitalizations for ALRI among these two age groups [10] to obtain the number and
rate (per 100,000 children per year) of pediatric influenza-associated hospitalizations, by
World Health Organization (WHO) region and United Nations (UN) country development
status.
Systematic Review of the Literature
We searched nine online databases (PubMed, Embase, Web of Science, CINAHL [Cumulative
Index to Nursing and Allied Health Literature], IndMed, LILACS [Literatura Latino-Ameri-
cana e do Caribe em Ciências da Saúde], WHOLIS [WHO Library Database], CNKI [China
National Knowledge Infrastructure], and the Global Health Database) to identify articles pub-
lished from 1 January 1996 to 1 June 2012. The search was conducted with no language restric-
tions, and full search terms are provided in S1 Table. Briefly, keywords included “influenza” or
“viral etiology” and other designators of respiratory illness such as “acute respiratory infection”
and “influenza-like illness”. Searches via the CNKI Chinese-language database were conducted
by native Mandarin speakers.
Identified articles were screened by two independent reviewers (two from K. E. L., M. W., E.
A.-B., M.-A. W., P. Glew, S. Mei, Z. Suizan) for inclusion in the analysis, and duplicates were
removed. The inclusion criteria were as follows: (1) original study with human participants, (2)
laboratory testing for influenza, with description of the type of diagnostic method used, (3)
minimum of 12 mo of continuous surveillance, (4) specified case definition (such as ALRI,
SARI, or acute respiratory illness) or other clear criteria for specimen collection and testing, (5)
hospitalized patients (excluding nosocomial infections), (6) number of enrolled cases from
whom clinical specimens were collected and found positive was provided, and (7) minimum of
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50 children (<18 y or “pediatric” as defined by authors) tested for influenza, in order to screen
out small, potentially unreliable studies from the study dataset. For title and abstracts that met
these criteria, full-text articles were obtained and re-screened. Full-text articles written in lan-
guages other than English were screened twice by co-investigators who could read the relevant
language. Any discrepancies were discussed and resolved by reviewers. Independent screening
was concordant for 92% of full-text articles, with 100% concordance after joint discussion of
discrepancies.
Key data from each eligible article were abstracted by two independent reviewers. Data
abstracted included the total number of inpatients tested and total positive for influenza by age
group and year, case definition and diagnostic test, WHO region, World Bank income level
(low, lower-middle, upper-middle, or high income) [11], and UN country development status
(industrialized or developing) [12].
Quality Assessment
Data quality for each eligible article was scored using a modified Newcastle–Ottawa checklist
for bias assessment [13], with a score of zero or one for each of the following sources of bias:
sampling process (explicit description of the sampling process for enrollment), case definition
(specificity of enrollment criteria), and outcome (clarity of reported results). We explored the
association between quality score and the percent positive using rank-sum non-parametric
tests among all eligible articles included in the pooled analysis.
Surveillance Data
To supplement data from published studies, we compiled data from surveillance platforms that
conducted hospital-based influenza surveillance. We established a working group, the Global
Respiratory Hospitalizations–Influenza Proportion Positive (GRIPP) Working Group. To be
eligible, surveillance platforms needed to conduct systematic year-round inpatient enrollment,
with testing for at least 12 mo and>50 pediatric patients. Forty-eight partners were contacted,
of which 37 had eligible data and agreed to participate. Data were collected using a standard
format. Variables included the number of persons tested and positive for influenza by calendar
year and age group, as well as surveillance system information such as the total number of
inpatient sites and case definition used. If surveillance data were also represented in a report
identified through the systematic review, the more detailed working group dataset was used,
and the published article was excluded as a duplicate source.
Statistical Analysis
We first described the median proportion positive by age group, study duration, calendar year,
number tested, diagnostic method, case definition, study population, WHO region, and coun-
try income level among all eligible datasets. We found substantial variation by age, diagnostic
test, and calendar year. To reduce the influence of data from less reliable diagnostic methods
(such as immunofluorescence [low sensitivity] and single serological samples [higher likeli-
hood of false-positive findings]), we restricted the data for the meta-analysis to sites that uti-
lized PCR for diagnosis, which is the accepted diagnostic gold standard. Further, to ensure that
pooled estimates reflected seasonal rather than pandemic years, we excluded data from 2009.
Pooled estimates of the proportion of respiratory hospitalizations due to influenza were cal-
culated by mixed regression model for each of the following age groups:<6 mo,<1 y,<2 y,
<5 y, 5–17 y, and<18 y. If a dataset used age ranges that did not line up with our definitions, it
was included in the smallest range that contained both bounds (e.g., a dataset from children
0–36 mo was included in the<5 y analysis). The same datasets could provide estimates for
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multiple age groups if they provided number tested and positive for influenza for each age
group.
The mixed regression model in SAS version 9.3 (SAS Institute) used a log-linked binomial
distribution of input values, and included the number tested and positive for influenza by data-
set and calendar year for each age group. If a single dataset provided data by year, then each
year was treated as a single observation in the model, and the dataset was defined as a cluster.
Random effects were accounted for at the dataset level, irrespective of the number of observa-
tions within the dataset.
We then applied our pooled proportion positive for influenza viruses to global estimates of
the total annual number of hospitalizations for ALRI among children<5 y and<1 y from Nair
et al. [10] and adjusted for 2012 population to calculate the total number of influenza-associ-
ated hospitalizations in these two age groups (for which denominators were available). For
children<5 y, we also applied stratified pooled estimates (by WHO region and UN country
development status) to the appropriate ALRI hospitalization denominators. We then divided
these total numbers of influenza-associated hospitalizations by total age-specific population (at
global and regional levels, and separately for developing and industrialized countries) to esti-
mate annual per capita influenza-associated hospitalization episodes [14].
No estimates of the frequency of ALRI among children under 6 mo existed to which we
could apply the proportion positive for influenza viruses. Therefore, we calculated an incidence
rate ratio of influenza-associated ALRI between children aged 0–5 mo and 6–11 mo, collected
as part of a separate study [6] (S2 Appendix). We applied this ratio to our estimate of the num-
ber of influenza-associated ALRI hospitalizations in children under 1 y, assuming uniform dis-
tribution of the population under 1 y, to estimate the number of influenza-associated
hospitalizations among children aged 0–5 mo.
Results
The systematic literature search identified 38,006 unique records from the nine scientific litera-
ture databases, of which 957 full-text articles were reviewed, and 108 included in the descriptive
analysis (Fig 1) (full list of included articles provided in S1 Appendix). In addition, 37 surveil-
lance datasets for periods ranging from 1 to 7 y, each with data from 1–49 inpatient facilities,
were provided by the GRIPP Working Group. Combined, the literature search and working
group resulted in a total of 145 unique data sources from 350 sites in 60 countries across all
WHO regions, including southern and northern hemisphere temperate climates as well as
tropical and arid regions of Asia and Africa. The two data sources combined covered a 31-y
period from 1982 to 2012. More than half (55/108, 51%) of the published studies had a 3/3
quality score. Compared to published articles, surveillance datasets were more recently col-
lected (median start year 2009 versus 2002), of longer duration (median duration 3 y versus 2
y), more likely to be PCR-based (41% versus 28%), and more likely to use the SARI case defini-
tion (84% versus 0%). Additionally, surveillance datasets were also more commonly from low-
income countries compared to published articles (41% versus 6%, respectively; Table 1).
The crude median percent of respiratory samples that were influenza positive among
patients aged 5–17 y was more than double that among those<5 y (15%, interquartile range
[IQR] 10%–22%, versus 6%, IQR 3%–9%, p< 0.001) and was also significantly higher in sur-
veillance data than in published articles (9%, IQR 6%–12%, versus 5%, IQR 3%–9%, p< 0.01)
(Table 2). The median percent positive was also significantly higher in 2009, when pandemic
influenza A(H1N1)pdm09 virus emerged, and in following years, compared to before 2009
(13% in 2009, IQR 6%–20%, versus 9% after 2009, IQR 5%–11%, and 5% before 2009, IQR
3%–9%, p< 0.001). The majority of the datasets (57%) comprised results from PCR diagnosis.
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Influenza positivity was significantly lower among the datasets that used immunofluorescence
alone, as compared to the datasets that used other methods such as PCR, culture, or a combina-
tion of diagnostic tests (3% versus 7%, p< 0.01). The frequency of influenza detection by any
Fig 1. Flow diagram for systematic review process.
doi:10.1371/journal.pmed.1001977.g001
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Table 1. Characteristics of published studies and surveillance data sources about influenza-associated respiratory illness among hospitalized
children, 1982–2012.
Characteristic Number (Percent) of Published Studies, n = 108,
1982–2010
Number (Percent) of Surveillance Datasets, n = 37,
2003–2012
Age group*
<6 mo 13 (12) 12 (32)
<1 y 20 (19) 23 (62)
<2 y 19 (18) 14 (38)
<5 y 45 (42) 35 (95)
5–17 y 9 (8) 28 (76)
<18 y 63 (58) 33 (89)
Study duration in years
1–2 78 (72) 16 (43)
3–4 19 (18) 13 (35)
5+ 11 (10) 8 (22)
Timeframe for outcome data**
Before 2009 93 (86) 12 (32)
During 2009 (“pandemic”) 1 (1) 18 (49)
After 2009 1 (1) 33 (89)
Total cases tested
50–99 10 (9) 1 (3)
100–499 46 (43) 9 (24)
500–999 21 (19) 5 (14)
1,000+ 31 (29) 22 (59)
Diagnostic test
PCR only 30 (28) 15 (41)
Immunoﬂuorescence only 32 (30) 0 (0)
Culture only 3 (3) 0 (0)
Multiple diagnostic tests, including
PCR
14 (13) 22 (59)
Multiple diagnostic tests, excluding
PCR
25 (23) 0 (0)
Other† 4 (4) 0 (0)
Case deﬁnition‡
Acute respiratory infection 35 (32) 1 (3)
ALRI 36 (33) 2 (5)
Pneumonia 18 (17) 1 (3)
SARI 0 (0) 31 (84)
Bronchiolitis 5 (5) 0 (0)
Other§ 14 (13) 2 (5)
Special populationǁ
Yes 7 (6) 0 (0)
No 101 (94) 37 (100)
WHO region
Africa 10 (9) 13 (35)
Americas 18 (17) 6 (16)
Eastern Mediterranean 2 (2) 2 (5)
Europe 30 (28) 2 (5)
Southeast Asia 11 (10) 6 (16)
Western Paciﬁc 37 (34) 8 (22)
(Continued)
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assay was not significantly associated with case definition used, income level, or WHO region.
To account for the possibility that differences in influenza positivity by age group were due to
confounding factors such as differences in PCR use or case definition applied, we analyzed
these factors by age group and found no association. The studies that did not use PCR were
similar to those that did use PCR by age group and timeframe of data reported. However, stud-
ies from the Americas and the Western Pacific (particularly South America and China) were
less likely to use PCR, with immunofluorescence as a more common diagnostic methodology.
Among published articles, there was also no difference in influenza positivity by quality score.
Due to steady increases in year-round hospital-based influenza surveillance over the past
decade, the number of available datasets substantially increased from 2006 (n = 2) to 2011 (n =
22). The overall median influenza percent positive increased sharply from 5% in 2008 to 13%
in 2009, largely driven by pandemic H1N1, the predominant subtype that year. The median
total percent positive (for any influenza type/subtype) dropped substantially in 2010 to 9% and
remained at 8% in 2011, as influenza A(H1N1)pdm09 circulated at lower levels and influenza
A(H3N2) and B predominated (Fig 2).
The pooled meta-analyses with only PCR-confirmed data included 63 datasets, each with 1
to 6 y of data, from 41 countries. The pooled percent positive for influenza among children
hospitalized with respiratory illness varied from 4.8% (95% CI 3.3%–6.9%) among those<6
mo to 16.4% (95% CI 13.6%–19.8%) among those 5–17 y, and was 9.5% (95% CI 8.1%–11.0%)
overall among children<18 y. Among children<5 y, the pooled estimate was 7.4% (95% CI
6.2%–8.8%). For this age group, we also stratified the pooled estimate by region and country
development status. We found the highest percent positive in Southeast Asia (8.5%, 95% CI
6.7%–10.8%) and the lowest in the Americas (4.6%, 95% CI 2.8%–7.4%), and the percent posi-
tive was lower in industrialized countries (5.9%, 95% CI 4.6%–7.5%) than in developing coun-
tries (7.7%, 95% CI 6.4%–9.3%), although these differences were not statistically significant.
Table 1. (Continued)
Characteristic Number (Percent) of Published Studies, n = 108,
1982–2010
Number (Percent) of Surveillance Datasets, n = 37,
2003–2012
World Bank income level
Low 7 (6) 15 (41)
Lower-middle 36 (33) 15 (41)
Upper-middle 20 (19) 6 (16)
High 47 (44) 1 (3)
Quality score (published studies
only)
0 5 (5)
1 20 (19)
2 28 (26)
3 55 (51)
*If a dataset used age ranges that did not line up with our deﬁnitions, it was included in the smallest range that contained both bounds (e.g., a dataset
from children 0–36 mo was included in the <5 y analysis).
**Pandemic deﬁned as calendar year 2009; 13 published articles provided only combined pre-pandemic/pandemic estimates.
†Includes serological ELISA of single or paired sera (n = 1) and other serological testing (n = 2).
‡Case deﬁnitions as deﬁned per individual study criteria.
§Includes acute respiratory infection and/or fever (n = 3), acute wheezing (n = 2), and other criteria (n = 8).
ǁDeﬁned as study being designed speciﬁcally to target a high-risk population; includes recurrent wheezing/asthma (n = 3), intensive care unit (n = 2),
cancer (n = 1), and HIV infection (n = 1).
doi:10.1371/journal.pmed.1001977.t001
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Table 2. Crude proportion of respiratory samples from hospitalized children testing positive for influenza by age group, study design, and
population.
Characteristic Number of Studies
(n = 141)
Median Number (IQR) Median Percent Positive (IQR) p-Value*
Tested Positive
Age group** <0.001
<6 mo 25 386 (148–1,129) 17 (3–32) 4 (1–5)
<1 y 42 536 (282–1,812) 34 (11–58) 4 (2–7)
<2 y 31 506 (145–1,322) 21 (4–77) 5 (2–8)
<5 y 80 766 (321–1,444) 42 (18–86) 6 (3–9)
5–17 y 36 243 (90–507) 27 (14–87) 15 (10–22)
<18 y 92 817 (239–1,524) 53 (15–110) 7 (5–12)
Data source 0.001
Surveillance 37 1,159 (469–2,185) 98 (38–249) 9 (6–12)
Published 104 435 (162–1,063) 29 (8–66) 5 (3–9)
Timeframe for outcome data† <0.001
Before 2009 102 454 (170–1,086) 29 (8–70) 5 (3–9)
During 2009 (“pandemic”) 19 610 (100–1,353) 56 (8–205) 13 (6–20)
After 2009 34 707 (291–1,289) 64 (20–118) 9 (5–11)
Diagnostic test 0.001
PCR only 44 701 (270–983) 40 (25–67) 7 (5–10)
Immunoﬂuorescence only 32 486 (185–1,654) 17 (8–78) 3 (2–6)
Culture only 3 302 (68–838) 39 (5–204) 13 (7–24)
Multiple diagnostic tests, including PCR 36 497 (185–1,167) 39 (18–88) 9 (8–10)
Multiple diagnostic tests, excluding PCR 22 1,047 (224–2,073) 64 (15–170) 8 (5–12)
Other 4 211 (143–1,389) 31 (7–75) 6 (4–13)
Case deﬁnition 0.14
Acute respiratory infection 33 958 (415–1,429) 51 (18–88) 5 (3–10)
ALRI 37 516 (186–1,234) 32 (17–77) 6 (3–9)
Pneumonia 19 136 (99–627) 12 (5–32) 7 (5–9)
SARI 31 1,159 (469–1,960) 91 (38–249) 8 (5–12)
Bronchiolitis 5 142 (118–170) 8 (3–8) 6 (3–16)
Other 16 278 (158–851) 29 (8–60) 7 (5–12)
Special population‡ 0.98
No 134 701 (196–1,369) 39 (14–84) 6 (4–10)
Yes 7 132 (119–293) 9 (7–20) 8 (2–9)
World Bank income level 0.08
Low 22 806 (387–1,256) 51 (34–108) 7 (4–9)
Lower-middle 49 808 (263–1,960) 52 (29–117) 8 (4–13)
Upper-middle 25 455 (184–1,429) 18 (9–70) 5 (2–9)
High 45 415 (143–1,031) 18 (7–66) 5 (5–7)
WHO region 0.55
Africa 23 817 (202–1,159) 45 (16–91) 7 (4–9)
Americas 24 299 (132–1,521) 17 (8–51) 5 (3–9)
Eastern Mediterranean 4 1,223 (534–1,621) 40 (21–141) 8 (3–14)
Europe 31 415 (142–916) 14 (7–66) 5 (3–7)
Southeast Asia 17 263 (186–627) 29 (7–62) 9 (5–14)
(Continued)
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There were no significant differences by country income status. Post hoc sensitivity analysis of
the effect of outliers (>95th percentile values) on the global estimates showed no difference.
Table 2. (Continued)
Characteristic Number of Studies
(n = 141)
Median Number (IQR) Median Percent Positive (IQR) p-Value*
Tested Positive
Western Paciﬁc 42 1,051 (412–2,077) 67 (39–98) 7 (4–11)
Four eligible articles provided data for inﬂuenza A only and were excluded from the overall positive analyses.
*Non-parametric comparisons conducted by Kruskal–Wallis/Wilcoxon rank-sum test. Age-based comparison conducted only between the <5 y and 5–17 y
age groups.
**Age groups include datasets that include a subset within the given range, but are non-duplicative, e.g., “<5 y” includes datasets of children 0–36 mo as
well as datasets of children 0–59 mo, but does not include datasets of children <1 y or <2 y.
†Pandemic deﬁned as calendar year 2009.
‡Deﬁned as study being designed speciﬁcally to target a high-risk population; includes recurrent wheezing/asthma (n = 3), intensive care unit (n = 2),
cancer (n = 1), HIV infection (n = 1).
doi:10.1371/journal.pmed.1001977.t002
Fig 2. Boxplot of the proportion of pediatric (0–17 y of age) respiratory samples testing positive for influenza virus among GRIPP datasets by year
and virus type/subtype.Data are for years with more than one dataset providing testing results by virus subtype. Unsubtyped influenza A viruses are
included in influenza A totals, but not shown separately. Boxplot excludes outside values.
doi:10.1371/journal.pmed.1001977.g002
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Finally, by applying the age-specific pooled proportion to a denominator of global hospitalized
ALRI episodes, we estimated the absolute number of influenza-associated hospitalizations among
children<5 y to be 870,000 (95% CI 610,000 to 1,237,000), for a per capita rate of 135/100,000
children/year (95% CI 95–193) (Table 3). The influenza-associated hospitalization rate in develop-
ing countries was 3-fold that in industrialized countries, and ranged from 174/100,000 children/
year in Africa to 71/100,000 children/year in the Americas. Among children<1 y, we estimated
374,000 (95% CI 264,000 to 539,000) influenza-associated hospitalizations per year worldwide.
The incidence of influenza-associated ALRI among children 0–5 mo was approximately 1.6
times higher than that of children 6–11 mo. Applying this rate ratio to the total influenza-asso-
ciated hospitalizations for children<1 y, we estimate 228,000 (95% CI 150,000 to 344,000)
influenza-associated hospitalizations per year among children aged less than 6 mo.
Discussion
We used influenza surveillance data from 350 sites in 60 countries to estimate that 10% of
global respiratory hospitalizations in children under 18 y worldwide were associated with influ-
enza. This proportion increased by age, with the highest percentage found among school-aged
Table 3. Pooled estimates of global pediatric influenza-associated hospitalizations per year, by age group, development status, andWHO region,
among studies using PCR diagnostic testing.
Characteristic N (Number of
Countries)
Pooled Percent
Positive (95%
CI)
Hospitalized ALRI
Episodes
(Thousands)*
Global Inﬂuenza-Associated
Hospitalizations (Thousands)
**
Inﬂuenza-Associated
Hospitalizations per 100,000
Children
Age group
<6 mo 15 (14) 4.8 (3.3–6.9) — — —
<1 y 26 (21) 6.1 (5.1–7.4) 6,136 (5,168–7,287) 374 (264–539) 284 (200–409)
<2 y 23 (18) 7.1 (6.1–8.4) — — —
<5 y 48 (35) 7.4 (6.2–8.8) 11,751 (9,837–12,054) 870 (610–1,237) 135 (95–193)
5–17 y 27 (22) 16.4 (13.6–19.8) — — —
<18 y 42 (32) 9.5 (8.1–11.0) — — —
Age <5 y by
development status
Industrialized 7 (4) 5.9 (4.6–7.5) 551 (408–745) 33 (19–56) 48 (28–81)
Developing 41 (31) 7.7 (6.4–9.3) 11,200 (9,429–13,309) 862 (603–1,238) 150 (105–216)
Age <5 y by WHO
region
Africa 16 (13) 8.2 (6.4–10.6) 3,084 (1,985–4,791) 253 (127–508) 174 (87–349)
Americas 7 (5) 4.6 (2.8–7.4) 1,333 (920–1,934) 61 (26–143) 79 (33–185)
Eastern
Mediterranean
1 (1) 7.4 (NA) 889 (628–1,258) 66 (46–93)† 95 (67–135)†
Europe 5 (4) 7.1 (1.5–32.7) 402 (252–642) 29 (4–210) 53 (7–387)
Southeast Asia 7 (4) 8.5 (6.7–10.8) 3,274 (2,008–5,341) 278 (135–577) 157 (76–326)
Western Paciﬁc 12 (8) 8.5 (6.8–10.6) 2,143 (1,660–2,764) 182 (113–293) 153 (95–246)
*Determined as described by Nair et al. [10] and adjusted for 2012 population.
**Point estimates and conﬁdence intervals were calculated as products of point estimates, lower bounds, and upper bounds (respectively) of pooled
percent inﬂuenza positive and total hospitalized ALRI episodes.
†Since 95% CI was not calculable on the percentage inﬂuenza positive in the Eastern Mediterranean region, variance in this region’s disease burden
estimates was derived only from the 95% CI of hospitalized ALRI episodes.
NA, not applicable.
doi:10.1371/journal.pmed.1001977.t003
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children (5–17 y). We further estimated that influenza causes approximately 374,000 respira-
tory hospitalizations per year in children<1 y of age (including 270,000 among those less than
6 mo) and 870,000 respiratory hospitalizations per year in children<5 y of age, with the great-
est impact in developing countries.
Although we did not identify any significant trends in the overall proportion positive by
WHO region in the crude analysis, the final pooled estimates among children<5 y from the
Americas differed from the global estimates (4.6%, 95% CI 2.8%–7.4%, versus 7.4%, 95% CI
6.2%–8.8%). This lower percentage positive for influenza may be related to the use of influenza
vaccine in the region, which has been on the rise since 2004 [15]. However, vaccine coverage
data among children in the region are limited, and these trends may also be a chance finding
due to the small number of study sites in this region reporting results of year-round influenza
testing.
Our findings on influenza burden among children<5 y are consistent with a previously
published estimate using fewer datasets and a different methodological approach [6] (870,000
annual influenza-associated hospitalizations worldwide in our analysis versus 911,000 esti-
mated by Nair et al., with overlapping confidence intervals) and demonstrate the value of using
non-population-based sentinel surveillance data for disease burden estimation. Our analysis
also found a substantially higher proportion of influenza-associated hospitalizations among
school-aged children (5–17 y), who are an important group for transmission of influenza virus
[7,16,17] and who were not included in previous global analyses. While the prevalence of influ-
enza as a proportion of respiratory hospitalizations is lower among younger children (<5 y
and particularly<1 y) than among older children, this is largely due to a high frequency of
other serious respiratory pathogens such as respiratory syncytial virus (RSV) [18]. These
young children experience the highest rate of total respiratory and influenza-associated hospi-
talizations [2,19]. Global pediatric mortality estimates suggest that the proportion of deaths
caused by influenza is highest among those aged 1–12 mo (2.8% of all deaths in this age group,
worldwide) [20]. Further, severe influenza infection with non-respiratory clinical presentation
is not captured in our analysis, so our calculation of the total burden of influenza-associated
hospitalization among the youngest children (<1 y) is likely an underestimate, as non-standard
presentations (such as fever without classic respiratory signs) are known to occur in this age
group [21].
Other pathogens, particularly Streptococcus pneumoniae and RSV, are also important causes
of respiratory hospitalizations in those<5 y. Globally, it is estimated that RSV is associated
with 25% of all ALRI in children<5 y, and, like influenza, RSV prevalence can vary substan-
tially by season and across geographic locations [18]. S. pneumoniae and Haemophilus influen-
zae type B were associated with 18.3% and 4.1% of severe ALRI episodes globally among
children<5 y in 2010, respectively [22], although their relative contributions to pediatric respi-
ratory hospitalizations may vary depending on their inclusion in pediatric vaccine programs.
However, a single ALRI episode may be caused by multiple pathogens, as well. For example,
severe bacterial pneumonia can be a sequela of influenza infection [23]; pediatric hospitaliza-
tions for invasive pneumococcal disease in the US have been shown to increase during the
2-wk window following peak circulation of influenza, as well as other respiratory viruses [24].
Our finding of an increased impact among children of pandemic influenza compared to sea-
sonal influenza (median estimate percent positive of 13% among children of all age groups in
2009 compared to 5% before 2009 and 9% after 2009) confirms previous findings of the effect
of the pandemic on ALRI hospitalizations worldwide. In the United States, a 5-fold rise was
reported in the rate of laboratory-confirmed influenza hospitalizations among children 5–17 y
of age during the 2009–2010 influenza pandemic compared to non-pandemic influenza sea-
sons [25]. Similar trends have been seen in India, where hospitalization rates due to pandemic
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influenza infection were particularly high among those 5–29 y, compared to other age groups
[26]. Global mortality data from the 2009 pandemic suggest that the actual number of deaths
was 15 times greater than laboratory-confirmed estimates, with 80% occurring in those youn-
ger than 65 y and 22% occurring in children 0–17 y [27].
Several important limitations should be considered when interpreting our findings. Differ-
ences in hospitalization practices, applications of case definitions, influenza testing practices
(including sampling method), and factors such as time from symptom onset to specimen col-
lection could make detection of influenza more or less likely and therefore bias the percent pos-
itive outcome. Our estimate of the burden of severe respiratory illness due to influenza is an
underestimate of total burden for several reasons. First, our approach does not allow estimation
of severe respiratory illness in individuals who did not present to hospital, which is particularly
a problem in resource-limited settings with poor health care access, where hospitalization rates
may be driven by proximity to a health care facility, limiting the generalizability of hospital-
based burden estimates. Second, individuals with influenza virus may have stopped shedding
by the time they presented to hospital and were tested, resulting in an underestimation of the
true percent positive. Lastly, we assumed that influenza virus detected in individuals hospital-
ized for respiratory disease was causal for the hospitalization episode. While influenza is rarely
found in well individuals [28], co-infections of influenza with bacteria and other viruses may
result in a more severe illness, which is not explored in our analysis.
Additionally, year-by-year variability of influenza percent positive and external factors,
such as co-infections and vaccination coverage, may affect influenza positivity. This year-by-
year variability is better captured in the GRIPP data than in the published data, which was
often not analyzable by both year and age group. Data from 2010 onward also include influenza
A(H1N1)pdm09, which may have had a greater impact on immunologically naïve children,
compared to other influenza viruses, during this period, resulting in an overestimate of annual
influenza burden. This may be particularly the case during 2010, when WHO officially transi-
tioned from pandemic to post-pandemic phase, especially in settings such as West Africa,
where influenza A(H1N1)pdm09 only began circulating in 2010 [29]. However, no significant
difference was seen in the overall pooled estimate when 2010 data were excluded, indicating
that influenza A(H1N1)pdm09 activity in 2010 is not likely to impact our overall findings on
proportion positive for seasonal influenza.
Our findings expand knowledge of the impact of severe influenza among children<1 and
<5 y, and create an evidence base for both younger (<6 mo) and older (5–17 y) children, for
whom, to our knowledge, no global estimates of influenza disease burden have been published
to date. Countries considering possible influenza vaccination programs for children and/or
pregnant women can use our estimates as inputs for vaccine impact and cost–benefit models.
Our data may also stimulate further research into the development of effective influenza vac-
cines for young children. Several recent changes have made influenza vaccination a more real-
istic goal in settings that have not previously considered influenza vaccination programs,
including 2012 WHO recommendations identifying pregnant women as the most important
target group for influenza vaccination [30], as well as recent expansions in vaccine manufactur-
ing and increasing investment into public health among middle-income countries [31]. As
demand and supply grow, vaccines may drop in cost, and targeting of pediatric populations
through childhood immunization programs such as the WHO Expanded Programme on
Immunization could further reduce the cost of implementation of an influenza vaccine pro-
gram. Maternal immunization is another strategy that would help reduce influenza burden in
children less than 6 mo [32]. The development of improved influenza vaccines is needed,
including products that require only one dose in young children or provide longer-term pro-
tection against a broader array of influenza viruses, such as live-attenuated and adjuvanted
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vaccines, as well as universal influenza vaccines that protect against multiple influenza strains.
Further research is also needed to better define the burden of influenza in young children, espe-
cially those presenting with non-respiratory symptoms, possibly via approaches such as vac-
cine probe studies [33].
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Editors' Summary
Background
Acute lower respiratory infections—bacterial and viral infections of the lungs and airways
(the tubes that take oxygen-rich air to the lungs)—are major causes of illness and death in
children worldwide. Pneumonia (infection of the lungs) alone is responsible for 15% of
deaths among children under five years old and kills nearly one million young children
every year. Globally, infections with respiratory syncytial virus and with Streptococcus
pneumoniae are associated with about 25% and 18.3%, respectively, of all episodes of
severe respiratory infection in young children. Another infectious organism that contrib-
utes to the global burden of respiratory disease among children is the influenza virus.
Every year, millions of people become infected with this virus, which infects the airways
and causes symptoms that include a high temperature, tiredness and weakness, general
aches and pains, and a dry chesty cough. Most infected individuals recover quickly, but
seasonal influenza outbreaks (epidemics) nevertheless kill about half a million people
annually, with the highest burden of severe disease being experienced by elderly people
and by children under five years old.
WhyWas This Study Done?
Annual immunization (vaccination) can reduce an individual’s risk of catching influenza,
but before a country implements this preventative measure, policymakers need reliable
estimates of the burden of influenza in their country. Although such estimates have been
calculated for resource-rich countries with temperate climates, where influenza largely
occurs in the winter, few estimates of influenza burden are available for resource-limited
countries, which has hampered informed consideration of vaccination for influenza pre-
vention in many settings. Recently, however, there has been a global expansion of system-
atic surveillance and testing for influenza virus among patients admitted to hospital for
severe respiratory infection. Here, the researchers use this expanded surveillance data to
provide an estimate of influenza-associated hospitalizations among children worldwide
between 1982 and 2012. Specifically, they undertake a systematic review to identify pub-
lished research articles on influenza-associated respiratory disease in hospitalized children,
and, by aggregating the data from these articles with data collected by hospital-based influ-
enza surveillance, they calculate a pooled estimate of the proportion of children hospital-
ized with respiratory disease who are positive for influenza.
What Did the Researchers Do and Find?
Using predefined search criteria, the researchers identified 108 published research articles
that provided information on influenza-associated respiratory illness among hospitalized
children. In addition, the Global Respiratory Hospitalizations–Influenza Proportion Posi-
tive (GRIPP) working group provided 37 hospital-based influenza surveillance datasets.
By aggregating the data from these sources using a statistical approach called meta-analy-
sis, the researchers calculated that, overall, influenza was associated with 9.5% of hospitali-
zations for severe respiratory infection among children under 18 years old worldwide,
ranging from 4.8% among children under six months old to 16.4% among children aged
5–17 years. The researchers also calculated that, on average over the study period, influ-
enza resulted in about 374,000 hospitalizations annually among children under one year
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old (including 228,000 hospitalizations among children less than six months old) and
nearly one million hospitalizations annually among children under five years old. Finally,
the researchers calculated that influenza-associated hospitalization rates among children
under five years old over the study period were more than three times higher in resource-
limited countries than in industrialized countries (150 and 48 hospitalizations, respec-
tively, per 100,000 children per year).
What Do These Findings Mean?
Differences in hospitalization practices, in applications of case definitions, and in influenza
testing protocols between settings may affect the accuracy of these findings. Specifically,
the approach taken by the researchers may mean that their estimate of the total burden of
severe respiratory disease due to influenza is an underestimate of the true situation. Even
so, these findings suggest that influenza is an important contributor to hospitalizations for
severe respiratory illness among children worldwide. Increasing influenza vaccination cov-
erage among young children and pregnant women could, therefore, reduce the contribu-
tion that influenza makes to hospitalizations for respiratory infections among children.
Importantly, the estimates of the burden of influenza provided by these findings can now
be used by countries considering influenza vaccination programs for children and/or preg-
nant women to help them investigate the possible health and cost implications of such
programs and should also stimulate further research into the development of effective
influenza vaccines for young children.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001977.
• The UK National Health Service Choices website provides information about
respiratory infections, seasonal influenza, influenza vaccination, and influenza
vaccination in children
• TheWorld Health Organization provides information on seasonal influenza (in several
languages) and on influenza vaccines
• The US Centers for Disease Control and Prevention also provides information for
patients and health professionals on all aspects seasonal influenza, including informa-
tion about vaccination, and about children, influenza, and vaccination; its website con-
tains a short video about personal experiences of influenza
• Flu.gov, a US government website, provides access to information on seasonal influenza
and vaccination
• MedlinePlus has links to further information about influenza and about vaccination (in
English and Spanish)
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